Track Ngm Biopharmaceuticals's net tangible assets ($150M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
As of the most recent data (December 2023), NGM shows a net tangible assets of $150M. That compares with $260M in the prior-year period — down 42.7% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, NGM's net tangible assets is now $150M (was $260M) — a 42.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Ngm Biopharmaceuticals is outperforming or lagging.
Tracking NGM's net tangible assets over time shows whether Ngm Biopharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $150M That compares with $260M in the prior-year period — down 42.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this net tangible assets page, Stockcircle has Ngm Biopharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net tangible assets (currently $150M) with ownership activity and broader fundamentals.
Ngm Biopharmaceuticals's net tangible assets is $150M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.